A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: A phase II study

Giuseppe Frasci, G. D'Aiuto, P. Comella, R. Thomas, G. Botti, M. Di Bonito, M. D'Aiuto, G. Romano, M. R. Rubulotta, G. Comella

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: A phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences